BlueCross BlueShield Federal Employee Program

RUBRACA
(rucaparib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    a. Deleterious *BRCA* mutation
    b. Complete or partial response to platinum-based chemotherapy
    c. Used as maintenance treatment

2. Metastatic castration-resistant prostate cancer (mCRPC)
    a. Deleterious *BRCA* mutation as detected by an FDA-approved test
    b. Previous treatment with androgen receptor-directed therapy and a taxane-based chemotherapy
    c. Patient has had a bilateral orchiectomy **OR** patient will be receiving a gonadotropin-releasing hormone (GnRH) analog concurrently

AND ALL of the following for **ALL** indications:

1. Prescriber agrees to do a complete blood count (CBC) at baseline and then monthly thereafter
2. Females of reproductive potential **only**: patient will be advised to use effective contraception during therapy and for 6 months after the last dose
3. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 3 months after the last dose

Prior - Approval Limits

Quantity

Strength	Quantity
200 mg	360 tablets per 90 days
250 mg	
300 mg	

RUBRACA
(rucaparib)

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
2. Metastatic castration-resistant prostate cancer (mCRPC)

AND ALL of the following for **ALL** indications:

1. Prescriber agrees to monitor complete blood counts (CBCs) monthly
2. **NO** disease progression or unacceptable toxicity
3. Females of reproductive potential **only**: patient will be advised to use effective contraception during therapy and for 6 months after the last dose
4. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 3 months after the last dose

Prior - Approval Limits

Same as above